香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* （股份代號：1877） 獲中國銀行間市場交易商協會接受註冊中期票據 本公告由上海君實生物醫藥科技股份有限公司（「本公司」）自願作出。請亦參見本 公司於2025年12月28日刊發的海外監管公告。 近日，本公司收到中國銀行間市場交易商協會（「交易商協會」）印發的《接受註冊 通知書》（中市協注[2025]MTN1249號）（「通知書」），交易商協會決定接受本公司 科技創新債券註冊。現就有關事項公告如下： 本公司將按照有關法律法規的要求及本公司股東會的授權，在規定的有效期內， 根據資金需求和市場情況擇機實施本次科技創新債券發行事宜，並按照相關規定 及時進行披露。 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 1 一、本公司本次註冊基礎品種為中期票據，註冊金額為人民幣20億元，註冊額度 自本通知書落款之日 ...

证券代码：688180 证券简称：君实生物 公告编号：临 2025-076 上海君实生物医药科技股份有限公司 关于收到中国银行间市场交易商协会 《接受注册通知书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海君实生物医药科技股份有限公司（以下简称"公司"）2024 年年度股东 大会审议通过了《关于发行境内外债务融资工具的一般性授权的议案》，同意公 司注册发行不超过人民币 25 亿元或等值外币的境内外债务融资工具，并一般及 无条件授权董事会并由董事会转授权董事长及其授权人士根据公司不时的需要 以及市场条件全权决定及办理债务融资工具发行的全部事宜，以及由董事会进一 步授权董事长及其授权人士根据公司需要以及其它市场条件等具体执行债务融 资工具发行事宜，详见公司在 2025 年 6 月 21 日于上海证券交易所网站 （www.sse.com.cn）等披露的《上海君实生物医药科技股份有限公司 2024 年年 度股东大会决议公告》（公告编号：临 2025-035）。 近日，公司收到中国银行间市场交易商协会（以下简称"交易 ...

Group 1 - The biopharmaceutical sector increased by 0.18% on December 25, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3959.62, up 0.47%, while the Shenzhen Component Index closed at 13531.41, up 0.33% [1] - Key stocks in the biopharmaceutical sector showed various performance, with Jindike (688670) rising by 4.66% to a closing price of 22.45 [1] Group 2 - The biopharmaceutical sector experienced a net outflow of 307 million yuan from institutional investors, while retail investors saw a net inflow of 359 million yuan [2] - Notable declines included Te Bao Biological (688278), which fell by 3.14% to a closing price of 80.90 [2] - The trading volume and turnover for various stocks in the sector varied significantly, with Wan Ze Co. (000534) achieving a turnover of 488 million yuan [1][2] Group 3 - Jindike (688670) had a net inflow of 25.23 million yuan from institutional investors, while retail investors had a net outflow of 23.95 million yuan [3] - Other stocks like Zhi Xiang Jin Tai (688443) and Shen Zhou Cell (688520) also showed mixed net inflows and outflows from different investor categories [3] - The overall trend indicates a divergence in investor sentiment, with institutional investors pulling back while retail investors increased their positions [2][3]

（来源：上观新闻） 12月23日下午，"聚力赋能，共创未来——临港集团生物医药产业专场对接会暨2025年度临创蓝湾基金 LP大会"在漕河泾会议中心圆满举行。本次大会聚焦生物医药核心赛道，致力于搭建园区产业与资本机 构精准对接、共生共赢的高端生态平台，为上海建设具有全球影响力的生物医药产业创新高地助力赋 能。中国科学院院士马大为、葛均波，市科委生物技术和医药处处长、二级巡视员曹宏明，临港集团副 总裁龚伟、总审计师熊国利，生物医药相关行业协会、产业发展联盟，投资机构以及企业代表出席活 动。 为强化创新投资赋能，临创资本与临创蓝湾基金向精准医学研究与产业发展联盟副主席、上海医学创新 发展基金会执行理事长王波、上海临床创新转化研究院副总裁王立言、国泰海通证券医疗健康行业负责 人王莉、道彤投资创始管理合伙人孙琦等行业顶尖专家颁发聘书，为基金投资决策、项目培育孵化、投 后管理赋能提供全方位支持。 现场，"核酸药物临床转化概念验证中心"正式启幕，标志着临港在生物医药细分赛道的生态布局进一步 完善。该中心由上海临床创新转化研究院和临港园区企业泰楚生物共同发起成立，聚焦核酸类创新药物 从早期研发到临床应用的转化瓶颈，构建覆盖核 ...

Core Viewpoint - Junshi Biosciences aims to establish itself as a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization, focusing on quality and innovation [2] Group 1: Company Overview - Junshi Biosciences was founded on December 27, 2012, and went public on July 15, 2020, specializing in the research and commercialization of monoclonal antibody drugs and other therapeutic proteins [7] - The company's main revenue sources include 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services [7] - As of September 30, 2023, Junshi Biosciences reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, a year-on-year increase of 35.72% [8] Group 2: Product Development and Pipeline - The company has developed a strong product pipeline, including its core product, Toripalimab, which is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and one supplemental NDA under review [2] - Toripalimab is also the first innovative biologic drug developed and produced in China to receive FDA approval, with approvals in multiple countries including the US, EU, and Australia [2] - Junshi Biosciences is also developing Tifcemalimab, the world's first anti-BTLA monoclonal antibody entering clinical development, with ongoing Phase III clinical trials and several Phase Ib/II studies in progress [2] Group 3: Collaborations and Innovations - On October 27, 2023, Junshi Biosciences announced collaborations with several institutions, including Peking University and the Chinese Academy of Sciences, to develop a monkeypox recombinant protein vaccine [3] - The company’s subsidiary, JunTuo Biotech, is involved in the preclinical development of vaccines for monkeypox and Zika virus [3] Group 4: Market Performance - On December 24, 2023, Junshi Biosciences' stock fell by 0.83%, with a trading volume of 277 million yuan and a market capitalization of 35.534 billion yuan [1] - The stock has experienced a net outflow of 32.026 million yuan from major investors, indicating a trend of reduced holdings over the past three days [4][5]

Core Insights - The conference focused on the biopharmaceutical industry, aiming to create a high-end ecological platform for industry and capital integration to support Shanghai's goal of becoming a global biopharmaceutical innovation hub [1] Group 1: Company Strategy and Development - Lingang Group has established 28 parks across 16 districts in Shanghai, housing over 24,000 enterprises, and is positioning itself as a leading service provider for innovative ecological integration in biopharmaceuticals [2] - The group emphasizes biopharmaceuticals as one of Shanghai's three strategic industries, with a focus on creating a "Life Blue Bay" in the Lingang New Area, fostering research and high-end manufacturing [2] - The company is transitioning from a "space provider" to an "ecosystem builder," leveraging a fund and base model to mobilize a fund scale of 170 billion yuan [2] Group 2: Industry Collaboration and Innovation - The "招投联动" (Investment and Recruitment Linkage) model is a key driver for empowering the biopharmaceutical ecosystem, integrating capital with industry innovation [4] - The establishment of the "Nucleic Acid Drug Clinical Transformation Concept Verification Center" aims to address bottlenecks in the development of nucleic acid drugs, providing comprehensive support from early research to clinical application [12] - The conference featured discussions on the internationalization of the biopharmaceutical industry, with insights from multinational companies and domestic innovators on building a comprehensive service system for global development [14] Group 3: Investment and Partnerships - Lingang Group's investment platform, including the Lingchuang Blue Bay Fund, has signed agreements with innovative companies like Tianchen Biotech and Orange Sail Medicine, focusing on dual-directional linkage between capital investment and industrial bases [8] - The partnership with Meifengli aims to integrate core advantages and resources in the medical device industry, enhancing the innovation service ecosystem in Shanghai [6] - The conference highlighted the importance of collaboration among industry experts to support investment decision-making and project incubation [10]

人民财讯12月24日电，企查查APP显示，近日，宁波甬元兴仑君金创业投资合伙企业(有限合伙)成立， 出资额5亿元，经营范围包含：创业投资(限投资未上市企业)。企查查股权穿透显示，该企业由君实生 物、宁波市甬元投资基金有限公司等共同出资。 ...

Core Viewpoint - The Hong Kong Stock Connect innovative drug sector is experiencing a rebound, with significant trading activity and price increases among leading innovative drug companies, indicating a positive shift in market sentiment towards this sector [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect innovative drug ETF (520880) reached a peak increase of 1.53% and traded over 140 million yuan during the session [1]. - Leading companies in the innovative drug sector, such as CSPC Pharmaceutical Group, recorded gains exceeding 5%, while others like 3SBio and Hengrui Medicine saw increases of over 2% [1]. Group 2: Investment Insights - Analysts from Zhongtai Securities noted that the current innovative drug market differs from the 2019-2021 period, as the sector is transitioning from narrative to actual performance, with trading volumes hitting new highs [1]. - Long-term support from domestic policies for innovative drugs is evident, with the introduction of commercial insurance directories enhancing payment capabilities [1][3]. - Changjiang Securities emphasized the emergence of a new policy support cycle for the pharmaceutical industry, particularly for innovative drugs, suggesting a focus on high-quality assets with strong overseas potential [3]. Group 3: ETF Characteristics - The Hong Kong Stock Connect innovative drug ETF (520880) is designed to track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has three key advantages: it exclusively includes innovative drug companies, has a high concentration of leading firms, and employs risk control measures for less liquid stocks [3][4]. - The top ten holdings in the ETF account for over 72% of its weight, showcasing the dominance of leading innovative drug companies [4]. Group 4: Alternative Investment Options - For investors seeking to mitigate volatility while still focusing on innovative drugs, the only ETF in the market (562050) offers a mix of innovative and traditional Chinese medicine stocks, providing a balanced approach [4].

Core Insights - The siRNA drug market is experiencing rapid growth, with the number of drugs in development reaching 289 in 2023, a growth rate of 103.52% since 2017, and projected to increase to 338 in 2024 [1][6] - The global siRNA drug market is expected to grow to $2.4 billion in 2024, with the U.S. market accounting for $1.3 billion, and is projected to reach $3.1 billion in 2025 [1][6] - siRNA drugs are primarily used for treating genetic and metabolic diseases, with ongoing research expanding their application to oncology, cardiovascular, neurological, and immune system diseases [1][6] siRNA Drug Industry Definition - siRNA (small interfering RNA) consists of double-stranded RNA fragments containing 19-23 base pairs, which target disease tissues for gene silencing through RNA interference (RNAi) mechanisms [2] Current Development Status - The siRNA drug market is characterized by significant potential in the biopharmaceutical field, particularly in oncology, with 17.9% of drugs targeting tumors [6] - The market is projected to see a substantial increase in both the number of drugs in development and market size, indicating a robust growth trajectory [1][6] Industry Chain - The siRNA drug industry chain includes upstream suppliers of high-purity RNA monomers and nucleotides, midstream drug development and production, and downstream applications in hospitals and medical institutions [7] Competitive Landscape - Since the first siRNA drug was approved in 2018, the market has seen significant clinical and commercial validation, with seven siRNA products approved globally by 2025 [9][10] - Domestic siRNA development is rapidly advancing, with several companies emerging as leaders in the field, such as Regeron and Saint Pharma [11] Industry Development Trends - siRNA drugs are gaining attention due to their unique mechanism and potential clinical efficacy in treating malignancies and genetic diseases [12] - The industry is expected to benefit from the participation of large pharmaceutical companies, enhancing creativity and competitiveness within the sector [12]

12月19日，港股三大指数高开高走，截至收盘，恒生指数上涨0.75%，恒生科技指数上涨1.12%，恒生国企指数上涨0.68%。 【导读】港股三大指数集体收涨 创新药、新能源汽车等涨幅靠前 具体来看，当日权重科技股集体上涨，腾讯、快手、网易、美团、百度均涨超1%。 板块方面，当日创新药概念股涨幅靠前，其中，映恩生物涨幅达9.29%，药明生物涨幅达4.4%。 | 代码 | 名称 | 现价 | 涨跌 | 涨跌幅 ▼ | | --- | --- | --- | --- | --- | | 9606 | 映恩生物-B | 336.600c | 28.600 | 9.29% | | 2269 | 药明生物 | 34.160c | 1.440 | 4.40% | | 6990 | 科伦博泰生物-B | 419.200c | 14.200 | 3.51% | | 1877 | 君实生物 | 23.240c | 0.760 | 3.38% | | 2162 | 康诺亚-B | 55.500c | 1.800 | 3.35% | | 2268 | 药明合联 | 70.000c | 2.050 | 3.02% | | 1530 | ...